Executive-Production

As a global integrated pharmaceutical company, Jubilant Pharma Limited offers a diverse range of products and services to customers worldwide. The business is structured into two main segments: Specialty Pharmaceuticals and Generics & APIs. Jubilant Generics (JGL), a subsidiary of Jubilant Pharma, has Research & Development units in Noida and Mysore, India, along with manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand. The Mysore facility, spread across 69 acres, is a USFDA approved site primarily focused on manufacturing APIs for Lifestyle driven Therapeutic Areas such as CVS and CNS. The Roorkee facility is a state-of-the-art site approved by multiple regulatory bodies including USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA, focusing on a B2B model for EU, Canada, and emerging markets. Both manufacturing units are supported by a team of around 500 research and development professionals based in Noida and Mysore. The R&D team is dedicated to developing new products in API, Solid Dosage Formulations, Sterile Injectable, Semi-Solids Ointments, Creams, and Liquids. The company conducts all BA/BE studies in-house at an 80 Bed facility with global regulatory accreditations. JGL's Regulatory Affairs & IPR professionals manage a unique portfolio of patents and product filings in both regulatory and non-regulatory markets. The company's revenue has shown consistent growth, reaching INR 53,240 Million during the Financial Year 2018-19, compared to INR 39,950 Million in the Financial Year 2017-18. For more information about Jubilant Pharma, please visit www.jubilantpharma.com.,